


inhibitor of CYP2CP and compound produced. Applicants respectfully traverse the requirements for restriction and election and request reconsideration.

It is urged that the above Groups are merely different embodiments of a single inventive concept for which a single patent should issue and do not constitute distinct inventions such as to require that the subject matter be prosecuted in separate patent applications. The inventions of Groups I, II and III are clearly related, the compounds having arisen from a singular research effort and having a common utility. Furthermore, since the compounds of Groups I and II have a core nucleus of structure there is not an undue burden on the Examiner with respect to searching the subject matter of the invention.

Accordingly, in view of the foregoing and further in view of the interest of efficiency and cost savings to both Applicants and the PTO, reconsideration and withdrawal of the requirement for restriction are requested. However, pursuant to 37 C.F.R. §§1.142 and 1.143, Applicants provisionally elect, subject to the traverse set forth above, Group I, covering claims 10-16, drawn to compound of Formula I, assay using said compound and method of making said compound. Applicants hereby reserve the right to file one or more divisional applications directed to the non-elected subject matter.

Favorable reconsideration of claims 10-20, withdrawal of the requirement for restriction, and allowance of this application with claims 10-20, are earnestly solicited.

Respectfully submitted,


Nora Stein-Fernandez
Attorney for Applicants
Registration No. 36,689

GLAXOSMITHKLINE
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-5044
Facsimile (610) 270-5090
N:\nsf\patapps\p32158\restrictionrequirement.doc